Company Profile

Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. Five of Vistagen’s clinical-stage neuroscience pipeline candidates belong to a new class of drugs known as pherines, which are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuitry in the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen’s sixth investigational candidate is an oral prodrug with potential to inhibit, but not block, NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders.



Management Team

Chief Executive Officer and Director
Chief Financial Officer
Chief Operating Officer
Chief Corporate Development Officer and General Counsel

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Vistagen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, CA 94080

Investor Relations Contact

Vistagen Therapeutics

Mark McPartland
Senior Vice President, Investor Relations
+1(650) 577-3606